Effects of AT1 receptor block begun late in life on normal cardiac aging in rats

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 4, 2003, Pages 573-580

  Saupe, Kurt W ^a,c   Sobol, Sophie C ^b   Koh, Stanley G ^b   Apstein, Carl S ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Aging; Angiotensin antagonist; Echocardiography; Hypertrophy; Rats

Indexed keywords

ADENOSINE; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN HEXETIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

AGED; AGING; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DOSE RESPONSE; ECHOCARDIOGRAPHY; EXERCISE; HEART FUNCTION; HEART LEFT VENTRICLE WALL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SIZE; HEART WEIGHT; HISTOPATHOLOGY; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TIBIA; ANIMAL; BLOOD PRESSURE; BODY WEIGHT; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; DRUG EFFECT; EXERCISE TOLERANCE; FISCHER 344 RAT; HEART; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HISTOLOGY; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ADENOSINE; AGING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; BODY WEIGHT; CORONARY VESSELS; EXERCISE TOLERANCE; HEART; HYPERTROPHY, LEFT VENTRICULAR; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; ORGAN SIZE; RATS; RATS, INBRED F344; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; TIBIA; VASCULAR RESISTANCE; VASODILATION;

EID: 0141641145     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200310000-00017     Document Type: Article

References (40)

1. Anversa P, Hiler B, Ricci R, et al. Myocyte cell loss and myocyte hypertrophy in the aging rat heart. J Am Coll Cardiol. 1986;8:1441-1448.
2. Burns TR, Klima M, Teasdale TA, et al. Morphometry of the aging heart. Mod Pathol. 1990;3:336-342.
3. Hachamovitch R, Wicker P, Capasso JM, et al. Alterations of coronary blood flow and reserve with aging in Fischer 344 rats. Am J Physiol. 1989;256:H66-H73.
4. Hinschen AK, Rosemeyer RB, Headrick JP. Age-related changes in adenosine-mediated relaxation of coronary and aortic smooth muscle. Am J Physiol Heart Circ Physiol. 2001;280:H2380-H2389.
5. Swynghedauw B, Besse S, Assayag P, et al. Molecular and cellular biology of the senescent hypertrophied and failing heart. Am J Cardiol. 1995;76:2D-7D.
6. Pugh KG, Wei JY. Clinical implications of physiological changes in the aging heart. Drugs Aging. 2001;18:263-276.
7. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 2002;105:85-92.
8. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-1621.
9. Sano M, Schneider MD. Still stressed out but doing fine: normalization of wall stress is superfluous to maintaining cardiac function in chronic pressure overload. Circulation. 2002;105:8-10.
10. Atkinson J, Tatchum-Talom R, Corman B. Effect of chronic ANG I-converting enzyme inhibition on aging processes. III. Endothelial function of mesenteric arterial bed of rat. Am J Physiol. 1994;267:R136-R143.
11. Ferder L, Romano LA, Ercole LB, et al. Biomolecular changes in the aging myocardium: the effect of enalapril. Am J Hypertens. 1998;11:1297-1304.
12. Inserra F, Romano L, Ercole L, et al. Cardiovascular changes by long-term inhibition of the renin-angiotensin system in aging. Hypertension. 1995;25:437-442.
13. Kreher P, Ristori MT, Corman B, et al. Effects of chronic angiotensin I-converting enzyme inhibition on the relations between ventricular action potential changes and myocardial hypertrophy in aging rats. J Cardiovasc Pharmacol. 1995;25:75-80.
14. Michel JB, Heudes D, Michel O, et al. Effect of chronic ANG I-converting enzyme inhibition on aging processes. II. Large arteries. Am J Physiol. 1994;267:R124-R135.
15. Maeso R, Rodrigo E, Munoz-Garcia R, et al. Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR. Kidney Int Suppl. 1998;68:S30-S35.
16. Maeso R, Rodrigo E, Munoz-Garcia R, et al. Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. J Hypertens. 1998;16:665-672.
17. Gonzalez Bosc LV, Kurnjek ML, Muller A, et al. Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging. J Hypertens. 2001;19:1403-1409.
18. Kim S, Iwao H. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype. J Hypertens Suppl. 1997;15:S3-S7.
19. Rizzoni D, Porteri E, Bettoni G, et al. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1998;32:798-806.
20. Tamura T, Said S, Andersen SM, et al. Temporal regression of myocyte hypertrophy in hypertensive, heart failure-prone rats treated with an AT1-receptor antagonist. J Card Fail. 2002;8:43-47.
21. Yoshiyama M, Takeuchi K, Omura T, et al. Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension. 1999;33:961-968.
22. Varo N, Iraburu MJ, Varela M, et al. Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension. 2000;35:1197-1202.
23. Varagic J, Susic D, Frohlich ED. Coronary hemodynamic and ventricular responses to angiotensin type 1 receptor inhibition in SHR: interaction with angiotensin type 2 receptors. Hypertension. 2001;37:1399-1403.
24. Heymes C, Swynghedauw B, Chevalier B. Activation of angiotensinogen and angiotensin-converting enzyme gene expression in the left ventricle of senescent rats. Circulation. 1994;90:1328-1333.
25. Heymes C, Silvestre JS, Llorens-Cortes C, et al. Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes. Endocrinology. 1998;139:2579-2587.
26. Kitzman DW. Diastolic heart failure in the elderly. Heart Fail Rev. 2002;7:17-27.
27. Riegger GA, Bouzo H, Petr P, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation. 1999;100:2224-2230.
28. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
29. Eberli FR, Weinberg EO, Grice WN, et al. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res. 1991;68:466-481.
30. Fletcher PJ, Pfeffer JM, Pfeffer MA, et al. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ Res. 1981;49:618-626.
31. Motz W, Strauer BE. Regression of structural cardiovascular changes by antihypertensive therapy. Hypertension. 1984;6:III133-III139.
32. Habib GB, Mann DL, Zoghbi WA. Normalization of cardiac structure and function after regression of cardiac hypertrophy. Am Heart J. 1994;128:333-343.
33. Welsh DC, Dipla K, McNulty PH, et al. Preserved contractile function despite atrophic remodeling in unloaded rat hearts. Am J Physiol Heart Circ Physiol. 2001;281:H1131-H1136.
34. Bunag RD, Teravainen TL. Tail-cuff detection of systolic hypertension in different strains of ageing rats. Mech Ageing Dev. 1991;59:197-213.
35. Li YM, Steffes M, Donnelly T, et al. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A. 1996;93:3902-3907.
36. Tuma RF, Irion GL, Vasthare US, et al. Age-related changes in regional blood flow in the rat. Am J Physiol. 1985;249:H485-H491.
37. Taal MW, Chertow GM, Rennke HG, et al. Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol Renal Physiol. 2001;280:F343-F355.
38. Ma LJ, Nakamura S, Whitsitt JS, et al. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PA1-1. Kidney Int. 2000;58:2425-2436.
39. Marin J, Rodriguez-Martinez MA. Age-related changes in vascular responses. Exp Gerontol. 1999;34:503-512.
40. Schwartzkopff B, Motz W, Frenzel H, et al. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation. 1993;88:993-1003.